California Public Employees Retirement System held its position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 114,300 shares of the biopharmaceutical company’s stock at the end of the 2nd quarter. California Public Employees Retirement System owned about 0.16% of Sangamo Therapeutics worth $1,006,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the company. HighTower Advisors LLC grew its position in shares of Sangamo Therapeutics by 0.3% during the 1st quarter. HighTower Advisors LLC now owns 39,405 shares of the biopharmaceutical company’s stock valued at $206,000 after acquiring an additional 100 shares during the period. Blair William & Co. IL boosted its holdings in Sangamo Therapeutics by 4.3% in the 2nd quarter. Blair William & Co. IL now owns 12,100 shares of the biopharmaceutical company’s stock worth $106,000 after buying an additional 500 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Sangamo Therapeutics by 0.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 128,764 shares of the biopharmaceutical company’s stock worth $670,000 after buying an additional 513 shares during the last quarter. Principal Financial Group Inc. boosted its holdings in Sangamo Therapeutics by 6.8% in the 2nd quarter. Principal Financial Group Inc. now owns 12,978 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 832 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its holdings in Sangamo Therapeutics by 0.6% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 267,293 shares of the biopharmaceutical company’s stock worth $2,353,000 after buying an additional 1,558 shares during the last quarter. Hedge funds and other institutional investors own 64.08% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Sangamo Therapeutics, Inc. (SGMO) Position Maintained by California Public Employees Retirement System” was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this article on another site, it was illegally copied and republished in violation of United States & international copyright laws. The correct version of this article can be read at https://www.watchlistnews.com/sangamo-therapeutics-inc-sgmo-position-maintained-by-california-public-employees-retirement-system/1699465.html.

In other Sangamo Therapeutics news, Director William R. Ringo sold 31,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 20th. The shares were sold at an average price of $14.37, for a total value of $445,470.00. Following the transaction, the director now directly owns 31,800 shares of the company’s stock, valued at approximately $456,966. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Curt A. Herberts III sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $15.25, for a total transaction of $228,750.00. The disclosure for this sale can be found here. Insiders sold a total of 61,000 shares of company stock worth $899,220 over the last three months. Corporate insiders own 5.50% of the company’s stock.

Shares of Sangamo Therapeutics, Inc. (NASDAQ SGMO) opened at $13.45 on Monday. The company has a quick ratio of 5.64, a current ratio of 5.64 and a debt-to-equity ratio of 0.02. Sangamo Therapeutics, Inc. has a twelve month low of $2.65 and a twelve month high of $17.06.

Sangamo Therapeutics (NASDAQ:SGMO) last released its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.04. Sangamo Therapeutics had a negative net margin of 157.66% and a negative return on equity of 31.81%. The business had revenue of $11.81 million for the quarter, compared to analyst estimates of $10.37 million. During the same period last year, the company posted ($0.27) EPS. The business’s revenue was up 333.0% on a year-over-year basis. sell-side analysts anticipate that Sangamo Therapeutics, Inc. will post -0.85 EPS for the current year.

Several equities research analysts recently issued reports on SGMO shares. Wells Fargo & Company reiterated an “outperform” rating and issued a $30.00 price objective (up from $20.00) on shares of Sangamo Therapeutics in a report on Tuesday, September 5th. Jefferies Group LLC reiterated a “buy” rating and issued a $18.00 price objective on shares of Sangamo Therapeutics in a report on Friday, October 13th. Zacks Investment Research cut Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, July 18th. BidaskClub cut Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, July 28th. Finally, Piper Jaffray Companies set a $8.00 price objective on Sangamo Therapeutics and gave the stock a “hold” rating in a report on Thursday, August 10th. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company. Sangamo Therapeutics presently has a consensus rating of “Hold” and an average target price of $14.40.

Sangamo Therapeutics Profile

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Want to see what other hedge funds are holding SGMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sangamo Therapeutics, Inc. (NASDAQ:SGMO).

Institutional Ownership by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.